Abatacept

Abatacept is superior to placebo in improving subclinical inflammation in patients who are at high risk for rheumatoid arthritis, and in slowing arthritis progression, at 6 months, according to data presented at ACR Convergence 2021.

Abatacept treatment after ustekinumab withdrawal did not prevent psoriasis relapse, according to a randomized clinical trial.

There is no increased risk for cancer overall associated with the long-term use of TNF inhibitors for rheumatoid arthritis, according to data published in Rheumatology.

The FDA granted priority review to abatacept for prevention of moderate to severe acute graft-versus-host disease among patients aged 6 years or older receiving unrelated donor hematopoietic stem cell transplantation.

Patients with rheumatoid arthritis who receive abatacept demonstrate similarly low rates of opportunistic infections as those treated with a placebo, according to data published in Arthritis Research & Therapy.

Upadacitinib is superior to abatacept in achieving remission and DAS28-CRP change, but is associated with more serious adverse events, among patients with rheumatoid arthritis refractory to biologic disease modifying antirheumatic drugs, according to data.

Although patients with rheumatoid arthritis who fail initial TNF therapy are more likely to switch to a second TNF inhibitor, those who swap to a non-TNF-inhibitor are more likely to continue with therapy, researchers reported.

The FDA granted breakthrough therapy designation to abatacept for prevention of moderate to severe acute graft-versus-host disease among individuals who undergo hematopoietic stem cell transplantation from unrelated donors.

HOUSTON — Primary immune deficiencies affect approximately 500,000 people in the United States, according to the National Institute of Allergy and Infectious Diseases.

ATLANTA — A panel at ACR/ARP 2019 offered an overview of the new guidelines for giant cell arteritis, Takayasu’s syndrome, and polyarteritis nodosa.